Premium
Efficacy of tnf‐α gene‐transduced tumor cells in treatment of established in vivo tumor
Author(s) -
Koshita Yoshikazu,
Lu Yue,
Fujii Shigeyuki,
Neda Hiroshi,
Matsuyama Tomohiko,
Satoh Yasushi,
Itoh Yoshinori,
Takahashi Minoru,
Kato Junji,
Sakamaki Sumio,
Watanabe Naoki,
Kohgo Yutaka,
Niitsu Yoshiro
Publication year - 1995
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910630123
Subject(s) - tumor necrosis factor alpha , splenocyte , immunity , cellular immunity , population , ctl* , immune system , vaccination , immunology , meth , in vivo , cancer research , biology , medicine , chemistry , cd8 , environmental health , monomer , organic chemistry , microbiology and biotechnology , acrylate , polymer
The therapeutic effect of TNF gene‐transduced mouse fibro‐sarcoma cells (Meth‐A: C5) on pre‐inoculated parental cells (Meth‐A: MO) was studied. Subcutaneous (s.c.) transplantation of MO cells into one flank of syngeneic BALB/c mice was followed by s.c. injection of irradiated MO or C5 into the opposite flank I week later. The initial MO tumor (T‐MO) completely regressed in C5‐vaccinated mice, whereas in Mo‐vaccinated mice continuous growth of T‐MO was observed. When a similar experiment was carried out in SCID mice, no regression of T‐MO was observed, suggesting that the tumor regression in BALB/c mice was not due to direct anti‐tumor activity of TNF secreted from C5, but to systemic immunity. Regression of the rechallenged MO tumor was observed in mice which had shown T‐MO regression by C5 vaccination, but rechallenged Colon 26 cells (syngeneic to BALB/c mice) continued to grow, indicating a specific immunity to Meth‐A cells. The systemic immunity evoked in C5‐vaccinated mice was directly demonstrated by enhanced killer activities of LAK and CTL with a proliferation of T‐cell population in their splenocytes. Abrogation of the therapeutic effect of C5 vaccination with anti‐Thy I and anti‐Lyt 2 also demonstrates the involvement of cellular immunity in tumor regression.